Call For India Compulsory Licenses For Last Resort TB Drugs
Public health campaigners in India and globally are pushing the government to allow Indian generic firms to make cheap copies of two new-generation, last resort antibiotics for drug-resistant tuberculosis through the use of patent-busting compulsory licenses.
You may also be interested in...
J&J To Build Capacity, Widen Access To Bedaquiline In India
J&J ties up with agencies, Indian government to build capacity and widen access to Sirturo for TB patients.
UN's TB Plan Emphasizes Drug Development Collaboration, Universal Access To Treatment
IFPMA attends UN General Assembly high-level meeting on tuberculosis, commits to partner on prevention, support systems, and research.
Mylan Gears To Make Otsuka’s MDR TB Drug In India
Manufacturing plans for multidrug-resistant tuberculosis (MDR-TB) drug Deltyba (delamanid) in India appear to be gathering steam, with partners Otsuka and Mylan commencing the technology transfer process for the product, although activists are concerned about the broader contours of the arrangement. Deltyba is also expected to be used in children and adolescents in India.